Owing to the improved efficacy, in 2020, the US Food and Drug Administration (FDA) approved margetuximab in combination with chemotherapy as the treatment of adult patients with metastatic ERBB2-positive breast cancer who have received two or more prior anti-ERBB2 regimens. This evidence concerns the gene ERBB2 and breast cancer.